Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.
Medscape Medical News
Source link
Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.
Medscape Medical News
Source link